AI summary · DOI: 10.64898/2026.11.12.762002 · bioRxiv: Genetics

LRPPRC gene replacement therapy preserves cardiac function and prevents premature death in a mouse model of mitochondrial disease

S. Zanin, F. Lager, M. Simon-Sola, C. Gaborit, G. Renault, F. Mingozzi, A. Rotig, M. Cavazzana,
and 2 more authorsM. Metodiev, B. Ruzzenente
Original paper Published on 13 Nov. 2026 bioRxiv preprint License: CC BY 4.0 Also in: fr

How to read this summary? Illustrated guide

The essentials

Compact single-AAV9 LRPPRC gene replacement preserved cardiac oxidative phosphorylation and function and markedly extended survival in knockout mice.

Based on the abstract only: check the details in the original paper.

Question

The study addresses whether LRPPRC gene replacement can overcome the AAV cargo-size constraint and prevent severe cardiac disease caused by LRPPRC deficiency. It also examines whether treatment rescues skeletal muscle in a tissue-specific knockout model.

Method

The researchers engineered compact single rAAV9 vectors expressing human or mouse LRPPRC and administered them intravenously to mice with Lrpprc knockout in heart and skeletal muscle. They assessed cardiac LRPPRC expression, oxidative phosphorylation, cardiomyopathy, survival, and skeletal muscle rescue; the abstract provides no sample sizes or detailed assessment methods.

Findings

  • Result The vectors restored cardiac LRPPRC expression and preserved oxidative phosphorylation function.
    See the passage in the paper
    This approach restored cardiac LRPPRC expression, preserved oxidative phosphorylation (OXPHOS) function, prevented cardiomyopathy and markedly extended survival.
  • Result Treatment prevented cardiomyopathy and markedly extended survival in the knockout mice.
    See the passage in the paper
    This approach restored cardiac LRPPRC expression, preserved oxidative phosphorylation (OXPHOS) function, prevented cardiomyopathy and markedly extended survival.
  • Result Skeletal muscle rescue was partial, while treatment prevented fatal cardiac dysfunction.
    See the passage in the paper
    While skeletal muscle rescue was partial, the therapy effectively prevented fatal cardiac dysfunction.
  • Authors’ interpretation The authors present the findings as in vivo proof of concept for AAV-mediated LRPPRC replacement in LRPPRC-linked mitochondrial disease.
    See the passage in the paper
    These findings provide the first in vivo proof-of-concept that AAV-mediated LRPPRC gene replacement can preserve OXPHOS function and prevent lethal cardiomyopathy, supporting its potential as a therapeutic strategy for mitochondrial disease linked to LRPPRC deficiency.

Limitations

  • Rescue in skeletal muscle was only partial.
    See the passage in the paper
    While skeletal muscle rescue was partial, the therapy effectively prevented fatal cardiac dysfunction.
  • The reported evidence is from a mouse knockout model, so the abstract does not establish efficacy in people.

Why it matters

The authors argue that compact AAV-mediated LRPPRC replacement can provide in vivo therapeutic proof of concept despite the gene’s size, particularly by preventing lethal cardiac dysfunction. The findings support further development of this approach for LRPPRC-linked mitochondrial disease.

Written by AI from the paper. Passages are checked word for word against the text we analysed; the rest may contain errors.

AI-generated keywords: LRPPRC; gene replacement; AAV9; mitochondrial disease; cardiomyopathy

Read further

  • Comprehensive Summary
  • Layman's Summary
  • Blog article
  • Original abstract
The paper investigates whether gene replacement can treat disease caused by a deficiency of LRPPRC, a protein required for mitochondrial gene expression. Pathogenic LRPPRC variants can cause severe mitochondrial disease, including neurological symptoms and damage to the liver or heart. A major challenge for gene therapy is that the LRPPRC coding sequence is too large to fit in an adeno-associated virus (AAV) vector alongside conventional regulatory elements. To address this challenge, the researchers developed compact recombinant AAV9 vectors carrying either human or mouse LRPPRC. They administered the vectors intravenously to mice with Lrpprc deleted specifically in the heart and skeletal muscle. The study tested whether delivering a replacement gene to these tissues could restore mitochondrial function, prevent heart disease, and extend survival. According to the abstract, treatment restored LRPPRC expression in the heart and preserved oxidative phosphorylation (OXPHOS), the mitochondrial process that produces most of the cell’s energy. Treated mice were protected from cardiomyopathy and had markedly extended survival. Rescue in skeletal muscle, however, was only partial. These results suggest that the strongest demonstrated benefit was preventing fatal cardiac dysfunction rather than fully correcting disease across all targeted tissues. The authors conclude that compact AAV9-mediated LRPPRC gene replacement can preserve cardiac mitochondrial function and prevent lethal cardiomyopathy in this mouse model. They describe the study as the first in vivo proof of concept for this strategy and suggest that it could provide a basis for treating LRPPRC-related mitochondrial disease. The findings are encouraging because they address the gene’s size-related delivery challenge and show a substantial survival benefit in an animal model. However, the available source contains only the title and abstract, not the full paper. It provides no numerical results for survival, cardiac function, LRPPRC expression, or OXPHOS, making it impossible to assess key effect sizes and experimental details. The abstract also does not report the number of animals, treatment dose or timing, follow-up duration, statistical analyses, adverse effects, or whether the human and mouse versions of the gene performed similarly. Because the model deletes Lrpprc in the heart and skeletal muscle, it may not reflect the full range of human disease, and its relevance to neurological or liver involvement remains unclear. The partial rescue in skeletal muscle also suggests that treatment benefits may vary by tissue. Finally, these are preclinical findings in mice; the abstract does not establish the therapy’s safety, effectiveness, or feasibility in people. Further research is needed to assess its durability, tissue distribution, and potential for clinical translation.

Was this synthesis useful?

Score: 0

Why do we need votes?

Votes are used to determine whether we need to re-run our summarizing tools. If the count reaches -10, our tools can be restarted.

Ask questions about this paper to our AI assistant

How to chat with this paper? Illustrated guide

You can also chat with multiple papers at once here.

Figures and plots

Ask about a figure by number or use its question button to request visual analysis. Up to two figures and four image panels per question. Values read from plots are approximate; check the original data.

AI assistant instructions?

Tools for this paper

Explain it differently 1 free rewrite left today
Save to a collection Group papers in collections to compare them, chat with them and export them. Continue with Google Create a free account Log in

Advanced tools Premium

For researchers who follow a field closely: citation alerts, journal-club slides, version comparison and Zotero export. Discover Premium

Zotero Zotero guide
Citation alerts Citation alerts guide
Weekly letter Presented in "Biology and medicine this week" of 16 November 2026. Biology and medicine this week: New jobs for cells, enzymes and genes · Receive one by email for free

Papers around this one

See them on a map

Ranked by how close their title and abstract are to this paper’s. Select some to read them together.

Closest papers

  1. Close Broader context
    PKR drives neuropathology in a mouse model of Leigh syndrome
    M. Gonzalez-Torres, P. Bianchi, M. Blanco-Ramos et al. · 2026 · bioRxiv preprint · AI summary available

    PKR drives mitochondrial neuropathology in Ndufs4-deficient Leigh syndrome mice, whereas this paper uses Lrpprc deficiency to study cardiac disease and gene replacement.

    In short

    PKR contributes to neurological decline and inflammation in Ndufs4-deficient mice, and its removal delays disease without restoring mitochondrial respiration.

  2. Close Broader context
    Prevention of prion disease symptoms in mice with deep PrP lowering
    J. E. Gentile, J. E. Farley, M. N. Kelemen et al. · 2026 · bioRxiv preprint · AI summary available

    This study lowers PrP with siRNA to prevent prion symptoms in mice, rather than replacing a mitochondrial disease gene with AAV.

    In short

    Deep PrP lowering with a C16-conjugated siRNA prevented symptoms through 500 days in prion-infected mice treated early and extended survival when treatment began after symptoms.

  3. Related
    Nationwide Functional Profiling Enables Clinical Reclassification of KCNH2 Variants in the French LQT2 Population
    B. Ribeiro de Oliveira, M. Alameh, S. Feliciangeli et al. · 2026 · medRxiv preprint · AI summary available
    In short

    Standardized functional profiling of 303 French KCNH2 variants integrated with MeTAL modeling and calibrated ACMG evidence to reclassify 64 VUS.

  4. Related Broader context
    Phosphatidylserine receptors are critical for lethal infection by Crimean-Congo hemorrhagic fever virus
    J. Berrigan, S. R. Monticelli, M. D. Ramirez et al. · 2026 · bioRxiv preprint · AI summary available

    This study blocks phosphatidylserine receptors to protect mice from viral disease, unlike this paper’s AAV treatment for LRPPRC-deficient cardiomyopathy.

    In short

    AXL, TIM-1, and TIM-4 support CCHFV entry and disease; deleting two receptors protected mice in a lethal-challenge model.

  5. Related Broader context
    CSF PrP-amyloid seeding predicts clinical onset in inherited prion disease
    T. H. Mok, A. Nihat, S. M. Vallabh et al. · 2026 · medRxiv preprint · AI summary available

    This study tests whether CSF prion seeding predicts clinical onset in mutation carriers, while this paper evaluates gene replacement in a mouse model.

    In short

    In PRNP E200K carriers, CSF RT-QuIC positivity preceded clinical onset and marked substantially elevated near-term conversion risk.

  6. Related Broader context
    Stem Cell Therapy for Alzheimer's Disease
    Ankur Patel, Grishma joshi, Rupali Ugile · 2016 · Neurons and Cognition · preprint, not peer reviewed · cited 88 times · AI summary available

    This review discusses stem cell therapy for Alzheimer’s disease, rather than AAV-mediated LRPPRC replacement for mitochondrial cardiomyopathy.

    Abstract

    The loss of neuronal cells in the central nervous system may happen in numerous neurodegenerative illnesses. Alzheimer's Disease (AD) is an intricate, irreversible, dynamic neurodegenerative sickness. It is the main source of age-related dementia, influencing roughly 5.3 million individuals in the United States alone. Promotion is a typical feeble ailment in individuals more than 65 years, bringing on disability described by decrease in memory, failure to learn and do every day exercises, intellectual weakness and influences the personal satisfaction of patients. Pathologic qualities of AD are an irregular development of specific proteins called Beta-amyloid "plaques" and Tau "Tangles" in th…

  7. Related Broader context
    Genome analysis and pleiotropy assessment using causal networks with loss of function mutation and metabolomics
    Azam Yazdani, Akram Yazdani, Sarah H. Elsea et al. · 2019 · Genomics · cited 25 times · AI summary available

    This study links loss-of-function mutations to serum metabolites using causal networks, whereas this paper tests LRPPRC gene replacement in knockout mice.

    Abstract

    Background: Many genome-wide association studies have detected genomic regions associated with traits, yet understanding the functional causes of association often remains elusive. Utilizing systems approaches and focusing on intermediate molecular phenotypes might facilitate biologic understanding. Results: The availability of exome sequencing of two populations of African-Americans and European-Americans from the Atherosclerosis Risk in Communities study allowed us to investigate the effects of annotated loss-of-function (LoF) mutations on 122 serum metabolites. To assess the findings, we built metabolomic causal networks for each population separately and utilized structural equation mode…

  8. Related Broader context
    Robin: A multi-agent system for automating scientific discovery
    Ali Essam Ghareeb, Benjamin Chang, Ludovico Mitchener et al. · 2025 · Artificial Intelligence · preprint, not peer reviewed · cited 91 times · AI summary available

    Robin automates scientific discovery workflows, while this paper experimentally tests gene replacement in a mouse model of mitochondrial disease.

    Abstract

    Scientific discovery is driven by the iterative process of background research, hypothesis generation, experimentation, and data analysis. Despite recent advancements in applying artificial intelligence to scientific discovery, no system has yet automated all of these stages in a single workflow. Here, we introduce Robin, the first multi-agent system capable of fully automating the key intellectual steps of the scientific process. By integrating literature search agents with data analysis agents, Robin can generate hypotheses, propose experiments, interpret experimental results, and generate updated hypotheses, achieving a semi-autonomous approach to scientific discovery. By applying this sy…

How are these papers found?

We compare the title and abstract of this paper with those of every paper summarized on this site, and with the papers Semantic Scholar recommends, those it cites and those citing it (for a much-cited paper, its most recent citations and, from OpenAlex, the most cited ones). Among the prior work and the follow-ups, the papers that use each other in depth, a method it uses and the much-cited follow-ups come a little higher. The levels (very close, close, related) come from the similarity of the texts, not from a judgment of quality; * marks a paper without an abstract, compared by its title. The sentence under a paper is written by an AI from the two abstracts: check it in the papers. A paper marked not relevant by three readers leaves the list.

Updated on 16 November 2026.

The illustrated guide to the papers around a paper

Disclaimer: The AI-based summarization tool and virtual assistant provided on this website may not always provide accurate and complete summaries or responses. We encourage you to carefully review and evaluate the generated content to ensure its quality and relevance to your needs.